Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Dexcom (DXCM)

DexCom appoints Glenn Boehnlein, former Stryker CFO, to its board of directors

Neutral Impact 3 of 5 leadership Written later

DexCom appointed Glenn S. Boehnlein as a director effective September 10, 2026, increasing the board to thirteen members. He joins the Audit Committee and the Operations & Innovation Committee, and the filing describes him as independent under Nasdaq listing standards.

Key points

  • Boehnlein most recently served as Vice President and Chief Financial Officer of Stryker Corporation from 2016 to 2025.
  • Initial equity grant of restricted stock units with a fair value of $500,000, vesting annually over three years.
  • Annual director equity grant expected around the 2027 Annual Meeting with a fair value of $347,500.
  • Term expires at the 2027 annual meeting of stockholders.

The filing

CompanyDexcom (DXCM)
Form8-K, current report
Filed with the SECSep 10, 2026, 4:16 PM ET
Accession number0001093557-26-000167

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:10 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 10, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.